Biomotion Competitors

Stocks . USA . 
Stock . Biomotion Sciences Ordinary
SLXN Stock   1.65  0.10  5.71%   
Biomotion Sciences competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Biomotion Sciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Biomotion Sciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Biomotion Sciences Correlation with its peers.

Biomotion Sciences vs Lipocine Correlation

Pay attention - limited upside

The correlation between Biomotion Sciences Ordinary and LPCN is -0.76 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biomotion Sciences Ordinary and LPCN in the same portfolio, assuming nothing else is changed.

Moving together with Biomotion Stock

  0.77DWTX Dogwood TherapeuticsPairCorr
  0.85EDIT Editas MedicinePairCorr

Moving against Biomotion Stock

  0.65IMMP Immutep Ltd ADRPairCorr
  0.54ENGN enGene Holdings CommonPairCorr
  0.53DSGN Design TherapeuticsPairCorr
  0.4663E ONWARD MEDICAL BVPairCorr
  0.34KYTX Kyverna TherapeuticsPairCorr
At this time, Biomotion Sciences' Return On Capital Employed is very stable compared to the past year. As of the 11th of February 2026, Return On Equity is likely to grow to 3.90, though Return On Tangible Assets are likely to grow to (6.27). At this time, Biomotion Sciences' Net Tangible Assets are very stable compared to the past year. As of the 11th of February 2026, Other Current Assets is likely to grow to about 1.3 M, while Total Assets are likely to drop about 2.4 M.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biomotion Sciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.081.628.47
Details
Intrinsic
Valuation
LowRealHigh
0.173.4710.32
Details
1 Analysts
Consensus
LowTargetHigh
8.199.009.99
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-2.06-1.51-0.96
Details

Biomotion Sciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Biomotion Sciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Biomotion and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Biomotion Sciences does not affect the price movement of the other competitor.

High positive correlations

BLRX
+ 0.84
GOVX
AIMD
+ 0.71
GOVX
AIMD
+ 0.64
BLRX
LPCN
+ 0.44
THAR
AIMD
+ 0.16
THAR
  

High negative correlations

LPCN
- 0.88
GOVX
LPCN
- 0.72
BLRX
LPCN
- 0.58
AIMD
THAR
- 0.33
GOVX
THAR
- 0.13
BLRX

Risk-Adjusted Indicators

There is a big difference between Biomotion Stock performing well and Biomotion Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biomotion Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Biomotion Sciences and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026
GOVX36.7 M(2.3 M)(2.1 M)(2.3 M)(2.7 M)(2.7 M)(3.3 M)(2.2 M)(2.6 M)(2.4 M)(2.9 M)(18.5 M)(14 M)(26 M)(25 M)(22.5 M)(21.4 M)
BLRX(32.1 M)(13.2 M)(20.4 M)(17.6 M)(10.2 M)(14.4 M)(15.8 M)(24.4 M)(23 M)(25.4 M)(30 M)(27.1 M)(25 M)(60.6 M)(9.2 M)(8.3 M)(8.7 M)
THAR(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(1.5 M)(2.4 M)(2.2 M)(8.5 M)(9.3 M)(12.2 M)(11 M)(10.4 M)
AIMD(300 K)(1.3 M)(650.8 K)(622.6 K)(622.6 K)(521.9 K)(670 K)(617.4 K)(1.3 M)(1.6 M)(1.5 M)(3.9 M)(14 M)(13.8 M)(14.9 M)(13.4 M)(12.7 M)
LPCN(5.2 K)(5.2 K)(76.7 K)(10.6 M)(20.4 M)(18.2 M)(19 M)(21 M)(11.7 M)(13 M)(21 M)(634.4 K)(10.8 M)(16.4 M)8.4 K7.5 K7.9 K

Biomotion Sciences and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Biomotion Sciences financial statement analysis. It represents the amount of money remaining after all of Biomotion Sciences Ordinary operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Biomotion Sciences Competitive Analysis

The better you understand Biomotion Sciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Biomotion Sciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Biomotion Sciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SLXN GOVX BLRX THAR AIMD LPCN
 5.71 
 1.65 
Biomotion
 5.90 
 2.55 
GeoVax
 0.66 
 3.07 
BioLineRx
 8.37 
 4.27 
Tharimmune
 0.54 
 1.86 
Ainos
 3.29 
 8.52 
Lipocine
Market Volatility
(90 Days Market Risk)
Very risky
Not too volatile
Somewhat reliable
Very risky
Dangerous
Moderately volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Good
Weakest
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Average
Risky
Low
Risky
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Hold
Hold
Hold
Sell
Hold
Strong Sell
Current Ratio
N/A
9.51 X
4.58 X
N/A
0.53 X
22.23 X
Net Asset
2.86 M
8.16 M
38.91 M
3.72 M
28.82 M
22.51 M
Profit Margin
N/A
N/A
(0.45) %
N/A
N/A
(1.27) %
EBITDA
(16.48 M)
(24.88 M)
3.92 M
(12.43 M)
(9.44 M)
(1.11 M)
Current Valuation
(1.75 M)
3.21 M
(1.29 M)
165.3 M
23 M
33.56 M
Price To Book
0.78 X
0.95 X
0.66 X
26.49 X
1.31 X
3.44 X
Operating Margin
N/A
(7.62) %
(7.58) %
N/A
(803.28) %
(29.34) %
Retained Earnings
(43.25 M)
(129.36 T)
(399.83 M)
(36.9 M)
(52.75 M)
(199.77 M)
Current Asset
N/A
1.24 M
48.18 M
N/A
N/A
29.41 M
Beta
-0.035
3.76
0.58
1.45
2.37
1.01
Number Of Employees
11
17
28
2
44
16
Shares Outstanding
3.13 M
1.73 M
4.26 M
39.53 M
4.77 M
5.55 M
Cash Flow From Operations
(8.4 M)
(24.68 M)
(43.87 M)
(10.9 M)
(5.81 M)
(1.22 M)
Total Debt
4.49 M
3.11 M
15.04 M
2.41 M
12 M
438.62 K
Return On Equity
-7.71
-3.77
-0.46
-2.25
-0.98
-0.33
Return On Asset
-0.78
-1.79
-0.15
-1.0
-0.31
-0.21
Number Of Shares Shorted
46.2 K
151.5 K
176.51 K
2.58 M
17.67 K
146.2 K
Book Value Per Share
2.23 X
4.13 X
0.01 X
0.85 X
2.68 X
2.61 X
Current Liabilities
N/A
126.99 K
3.14 M
N/A
N/A
1.57 M
Total Asset
2.86 M
8.16 M
38.91 M
3.72 M
28.82 M
22.51 M
Short Ratio
0.80 X
0.67 X
6.15 X
2.67 X
0.04 X
0.64 X
Target Price
9.0
204.63
26.0
5.0
N/A
10.88
Debt To Equity
N/A
0.01 %
0.05 %
N/A
5.29 %
0.01 %
Shares Owned By Institutions
5.10 %
8.05 %
1.07 %
13.17 %
0.60 %
18.66 %
Market Capitalization
5.47 M
4.61 M
15.18 M
172.75 M
12.31 M
49.36 M
Price To Earning
N/A
(1.25) X
(3.88) X
N/A
N/A
15.80 X
Price To Earnings To Growth
N/A
N/A
0.20 X
N/A
N/A
N/A
Price To Sales
N/A
1.37 X
1.11 X
N/A
116.13 X
11.42 X
Net Income
(16.52 M)
(24.99 M)
(9.22 M)
(12.2 M)
(14.86 M)
8.35 K
Earnings Per Share
349.09 X
(31.75) X
(6.00) X
(3.68) X
(4.52) X
(1.02) X
Shares Owned By Insiders
4.60 %
0.35 %
3.99 %
20.60 %
56.46 %
2.84 %
Revenue
N/A
3.95 M
28.94 M
N/A
20.73 K
11.2 M
Working Capital
(1.27 M)
4.83 M
11.7 M
1.31 M
382.86 K
20.81 M
Cash And Equivalents
N/A
30.9 M
43.15 M
N/A
1.75 M
37.4 M
Cash Per Share
N/A
1.25 X
0.90 X
N/A
0.09 X
0.42 X
Gross Profit
N/A
(19.38 M)
10.23 M
N/A
91.23 K
4.32 M
Day Typical Price
1.7
2.55
3.06
4.26
1.86
8.52
Accumulation Distribution
3893.48
N/A
0.0065
N/A
0.0054
N/A
Market Facilitation Index
0.0
N/A
0.02
N/A
0.01
N/A
Daily Balance Of Power
(0.62)
0
1.0
0
1.0
0
Period Momentum Indicator
(0.10)
(0.16)
0.02
(0.39)
0.01
(0.29)
Rate Of Daily Change
0.94
0.94
1.01
0.92
1.01
0.97
Day Median Price
1.73
2.55
3.06
4.26
1.86
8.52
Price Action Indicator
(0.13)
(0.08)
0.02
(0.19)
0.01
(0.15)
Coefficient Of Variation
(952.63)
(378.55)
(1,998)
1460.99
(1,054)
322.42
Mean Deviation
4.5
5.35
2.48
5.28
4.5
5.03
Jensen Alpha
(0.90)
(2.30)
(0.24)
0.3237
(0.89)
2.11
Total Risk Alpha
(1.38)
(2.90)
(0.48)
(0.24)
(1.34)
1.39
Sortino Ratio
N/A
N/A
N/A
0.0546
N/A
0.4145
Downside Variance
N/A
N/A
N/A
41.69
N/A
23.56
Standard Deviation
6.57
7.86
3.06
6.51
6.73
6.78
Kurtosis
2.1
3.94
(0.32)
(0.29)
2.69
1.0
Potential Upside
15.09
9.38
4.95
11.15
12.3
15.95
Treynor Ratio
(0.30)
(0.80)
(0.18)
0.3222
(0.22)
(8.95)
Maximum Drawdown
37.24
42.89
13.04
29.73
38.73
33.09
Variance
43.17
61.82
9.39
42.35
45.23
46.03
Market Risk Adjusted Performance
(0.29)
(0.79)
(0.17)
0.3322
(0.21)
(8.94)
Risk Adjusted Performance
(0.08)
(0.20)
(0.03)
0.0636
(0.07)
0.2571
Skewness
0.9755
(0.53)
0.1316
(0.16)
0.9699
0.9765
Semi Deviation
N/A
N/A
N/A
5.94
N/A
3.28
Information Ratio
(0.12)
(0.28)
(0.08)
0.0542
(0.11)
0.2965
Value At Risk
(9.15)
(13.70)
(5.26)
(10.08)
(10.43)
(7.33)
Expected Short fall
N/A
N/A
N/A
(5.72)
N/A
(5.95)
Downside Deviation
N/A
N/A
N/A
6.46
N/A
4.85
Semi Variance
N/A
N/A
N/A
35.29
N/A
10.75

Biomotion Sciences Competition Performance Charts

Five steps to successful analysis of Biomotion Sciences Competition

Biomotion Sciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Biomotion Sciences in relation to its competition. Biomotion Sciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Biomotion Sciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Biomotion Sciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Biomotion Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Biomotion Sciences position

In addition to having Biomotion Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cancer Fighters Thematic Idea Now

Cancer Fighters
Cancer Fighters Theme
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Biomotion Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomotion Sciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomotion Sciences Ordinary Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomotion Sciences Ordinary Stock:
How To Invest In Biomotion
Details
Is Biomotion Stock a good investment?
Details
What is Biomotion Sciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Biomotion Sciences Correlation with its peers.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could Biomotion diversify its offerings? Factors like these will boost the valuation of Biomotion Sciences. If investors know Biomotion will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomotion Sciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
349.09
Return On Assets
(0.78)
Return On Equity
(7.71)
The market value of Biomotion Sciences is measured differently than its book value, which is the value of Biomotion that is recorded on the company's balance sheet. Investors also form their own opinion of Biomotion Sciences' value that differs from its market value or its book value, called intrinsic value, which is Biomotion Sciences' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Biomotion Sciences' market value can be influenced by many factors that don't directly affect Biomotion Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Biomotion Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomotion Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Biomotion Sciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY